FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Fulcrum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.70+0.05 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
86M of 76M shares
Institutional holders
155
29 new, 42 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
6 buys · 9 sales
Net sold $57.67M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin Tang | 6,913,329 | 10.40% | 13G (passive) amendment | Jul 13, 2026 |
| Peter Kolchinsky | 6,649,973 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| RA Capital Management, L.P. | 6,053,960 | 11.20% | 13G (passive) amendment | Dec 8, 2025 |
| Oleg Nodelman | 6,000,000 | 9.00% | 13G (passive) | Jun 17, 2026 |
| EcoR1 Capital, LLC | 6,000,000 | 9.00% | 13G (passive) | Jun 17, 2026 |
| Wilmot B. Harkey | 5,475,040 | 8.22% | 13G (passive) | Jun 30, 2026 |
| Chen Yu | 5,250,000 | 7.90% | 13G (passive) amendment | Mar 31, 2026 |
| Suvretta Capital Management, LLC | 5,067,394 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 4,802,880 | 7.20% | 13G (passive) amendment | Jun 30, 2026 |
| Nantahala Capital Management, LLC | 4,777,912 | 7.66% | 13G (passive) | Sep 30, 2024 |
| Adage Capital Management, L.P. | 4,589,000 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
| Bank Of America Corp /De/ | 4,468,123 | 6.70% | 13G (passive) | Jun 30, 2026 |
| BlackRock Portfolio Management LLC | 4,021,379 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Montanova Capital, LLC | 3,680,921 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FULC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10,950,080 | 14.35% | $40.08M | +7,900,040 | 0.67% |
| BlackRock, Inc. | 8,824,259 | 11.57% | $32.30M | +3,433,666 | 0.00% |
| EcoR1 Capital, LLC | 6,549,866 | 8.58% | $23.97M | New | 1.17% |
| Tang Capital Management LLC | 6,521,412 | 8.55% | $23.87M | New | 1.08% |
| Suvretta Capital Management, LLC | 3,680,921 | 4.82% | $13.47M | −2,880,190 | 0.25% |
| D. E. Shaw & Co., Inc. | 3,044,385 | 3.99% | $11.14M | +1,421,104 | 0.01% |
| Citadel Advisors LLC | 2,704,505 | 3.54% | $9.90M | +1,412,019 | 0.00% |
| Vanguard Capital Management LLC | 2,697,216 | 3.54% | $9.87M | +4,268 | 0.00% |
| Jane Street Group, LLC | 2,217,498 | 2.91% | $8.12M | +1,907,081 | 0.00% |
| State Street Corp | 2,037,025 | 2.67% | $7.46M | +487,174 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 2,000,000 | 2.62% | $7.32M | +1,600,000 | 0.01% |
| GSK plc | 1,785,714 | 2.34% | $6.54M | – | 1.09% |
| Qube Research & Technologies Ltd | 1,748,467 | 2.29% | $6.40M | +773,728 | 0.01% |
| Assenagon Asset Management S.A. | 1,670,408 | 2.19% | $6.11M | +476,535 | 0.00% |
| Renaissance Technologies LLC | 1,647,800 | 2.16% | $6.03M | +1,634,200 | 0.01% |
| ADAR1 Capital Management, LLC | 1,565,029 | 2.05% | $5.73M | +1,434,469 | 0.26% |
| Millennium Management LLC | 1,485,803 | 1.95% | $5.44M | +1,129,332 | 0.00% |
| Geode Capital Management, LLC | 1,432,133 | 1.88% | $5.24M | −54,409 | 0.00% |
| Marshall Wace, Llp | 1,358,423 | 1.78% | $4.97M | New | 0.00% |
| UBS Group AG | 1,253,909 | 1.64% | $4.59M | +938,724 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 86M | 100.0% | 29 / 73 | 34 / 42 | 47M | 33M |
| Q1 2026 | 169 | 72M | 94.0% | 37 / 73 | 39 / 38 | 17M | 10M |
| Q4 2025 | 172 | 68M | 88.6% | 59 / 44 | 49 / 16 | 23M | 10M |
| Q3 2025 | 129 | 54M | 70.5% | 26 / 41 | 42 / 18 | 7M | 7M |
| Q2 2025 | 122 | 54M | 71.3% | 24 / 34 | 46 / 19 | 7M | 4M |
| Q1 2025 | 117 | 51M | 67.3% | 18 / 32 | 42 / 19 | 4M | 5M |
| Q4 2024 | 119 | 52M | 68.1% | 24 / 33 | 40 / 33 | 8M | 11M |
| Q3 2024 | 130 | 55M | 72.2% | 44 / 31 | 35 / 34 | 24M | 29M |
| Q2 2024 | 121 | 65M | 85.0% | 31 / 45 | 26 / 36 | 12M | 10M |
| Q1 2024 | 126 | 63M | 82.4% | 36 / 34 | 28 / 11 | 8M | 8M |
| Q4 2023 | 101 | 62M | 81.7% | 31 / 24 | 21 / 11 | 11M | 6M |
| Q3 2023 | 81 | 57M | 74.2% | 15 / 17 | 26 / 21 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FULC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,074,332 | 2.72% | $7.59M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,552,712 | 2.04% | $5.68M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 807,587 | 1.06% | $2.96M | 0.69% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 646,379 | 0.85% | $2.31M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 567,824 | 0.74% | $2.08M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 553,375 | 0.73% | $2.03M | 0.00% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 416,770 | 0.55% | $2.88M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 398,072 | 0.52% | $1.46M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 306,585 | 0.40% | $2.12M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 251,883 | 0.33% | $1.74M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 228,499 | 0.30% | $1.58M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 199,458 | 0.26% | $730.02K | 0.05% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 168,604 | 0.22% | $603.60K | 0.01% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 162,121 | 0.21% | $593.36K | 0.02% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 157,099 | 0.21% | $562.41K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alex Sapir | See Remarks, Director | 193,360 | 0.25% | Feb 4, 2026 |
| Alan A. Musso | Chief Financial Officer | 0 | – | Feb 4, 2026 |
| Greg Tourangeau | Principal Accounting Officer | 14,062 | 0.02% | Feb 4, 2026 |
| Curtis Gale Oltmans | Chief Legal Officer | 10,252 | 0.01% | Feb 4, 2026 |
| Alan Ezekowitz | Director | 10,927 | 0.01% | Jul 2, 2026 |
| James A. Geraghty | Director | 90,714 | 0.12% | Jul 2, 2026 |
| Katina Dorton | Director | 0 | – | Jul 2, 2026 |
| Robert J. Gould | Director | 454,864 | 0.60% | Jul 2, 2026 |
| Kate Haviland | Director | – | – | Jul 2, 2026 |
| Colin Hill | Director | 0 | – | Jul 2, 2026 |
| Sonja Banks | Director | 0 | – | Jul 2, 2026 |
| Rachel K. King | Director | – | – | Jul 2, 2026 |
| Joshua Lehrer-Graiwer | Director | 0 | – | May 1, 2026 |
| Kevin Tang | 10% owner | 7,080,945 | 9.28% | Jul 20, 2026 |
| Capital Management Llc Tang | 10% owner | 6,913,329 | 9.06% | Jul 20, 2026 |
| Peter Kolchinsky | 10% owner | 9,505,925 | 12.46% | Dec 10, 2025 |
| Rajeev M. Shah | 10% owner | 3,109,704 | 4.08% | Dec 10, 2025 |
| Capital Healthcare Fund LP RA | 10% owner | 6,145,682 | 8.05% | Dec 10, 2025 |
| Ra Capital Management, L.P. | 10% owner | 10,229,099 | 13.41% | Dec 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin Tang 10% owner | Jul 17, 2026 | Buy | +50,945 | $3.52 | $179.33K | 7,080,945 |
| Kevin Tang 10% owner | Jul 16, 2026 | Buy | +116,671 | $3.56 | $415.35K | 7,030,000 |
| Capital Management Llc Tang 10% owner | Jul 15, 2026 | Buy | +107,377 | $3.56 | $382.26K | 6,913,329 |
| Capital Management Llc Tang 10% owner | Jul 14, 2026 | Buy | +53,651 | $3.56 | $191.00K | 6,730,000 |
| Capital Management Llc Tang 10% owner | Jul 14, 2026 | Buy | +75,952 | $3.58 | $271.91K | 6,805,952 |
| Capital Management Llc Tang 10% owner | Jul 13, 2026 | Buy | +12,966 | $3.54 | $45.90K | 6,676,349 |
| Alan Ezekowitz Director | Jun 26, 2026 | Sale(10b5-1 plan) | −18,000 | $3.65 | $65.70K | 10,927 |
| Robert J. Gould Director | Feb 2, 2026 | Sale(10b5-1 plan) | −15,000 | $10.72 | $160.80K | 454,864 |
| Robert J. Gould Director | Jan 2, 2026 | Sale(10b5-1 plan) | −15,000 | $10.87 | $163.05K | 469,864 |
| Robert J. Gould Director | Jan 2, 2026 | Sale(10b5-1 plan) | −15,000 | $11.87 | $178.05K | 469,864 |
| Curtis Gale Oltmans Chief Legal Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −3,452 | $12.92 | $44.60K | 10,252 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −2,706,397 | $14.28 | $38.65M | 6,145,682 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −91,722 | $14.98 | $1.37M | 6,053,960 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −1,377,020 | $13.33 | $18.36M | 8,852,079 |
| Robert J. Gould Director | Nov 19, 2025 | Sale(10b5-1 plan) | −15,000 | $11.03 | $165.45K | 484,864 |
| Greg Tourangeau Principal Accounting Officer | May 8, 2025 | Sale | −498 | $5.06 | $2.52K | 14,062 |
| Rajeev M. Shah 10% owner | Aug 21, 2024 | Other | −8,500,000 | – | – | 3,109,704 |
| Alex Sapir See Remarks, Director | Jul 3, 2024 | Option exercise | +150,000 | $3.27 | $490.50K | 193,360 |
| Greg Tourangeau Principal Accounting Officer | May 7, 2024 | Sale | −236 | $7.76 | $1.83K | 11,571 |
| Greg Tourangeau Vice President, Finance | Mar 8, 2024 | Sale | −4,884 | $11.72 | $57.24K | 11,807 |
| Alex Sapir See Remarks, Director | Mar 4, 2024 | Buy | +43,360 | $11.35 | $492.14K | 43,360 |
| Greg Tourangeau Principal Accounting Officer | May 10, 2023 | Sale | −210 | $3.31 | $695 | 15,992 |
| Ra Capital Management, L.P. 10% owner | Jan 20, 2023 | Buy | +1,923,076 | $13.00 | $25.00M | 11,609,704 |
| Robert J. Gould Interim President & CEO, Director | Jan 13, 2023 | Sale(10b5-1 plan) | −6,766 | $15.00 | $101.49K | 499,864 |
| Capital Healthcare Fund LP RA 10% owner | Jan 4, 2023 | Buy | +122,334 | $7.03 | $860.01K | 9,628,259 |
| Capital Healthcare Fund LP RA 10% owner | Jan 4, 2023 | Buy | +58,369 | $7.80 | $455.28K | 9,686,628 |
| Peter Kolchinsky 10% owner | Dec 27, 2022 | Buy | +4,089 | $5.99 | $24.49K | 9,505,925 |
| Peter Kolchinsky 10% owner | Dec 19, 2022 | Buy | +98,787 | $5.90 | $582.84K | 9,501,836 |
| Ra Capital Management, L.P. 10% owner | Dec 16, 2022 | Buy | +1,341,420 | $5.42 | $7.27M | 9,403,049 |
| Ra Capital Management, L.P. 10% owner | Dec 15, 2022 | Buy | +237,029 | $5.50 | $1.30M | 8,061,629 |
| Ra Capital Management, L.P. 10% owner | Dec 14, 2022 | Buy | +824,600 | $5.46 | $4.50M | 7,824,600 |
| Trv Gp Iii, Llc 10% owner | Dec 13, 2022 | Other | −2,000,000 | – | – | 1,962,202 |
| Robert J. Gould Director | Jun 7, 2022 | Option exercise | +71,435 | $7.84 | $560.05K | 578,065 |
| Robert J. Gould Director | Jun 7, 2022 | Sale(10b5-1 plan) | −71,435 | $8.09 | $577.91K | 506,630 |
| Robert J. Gould Director | Jun 6, 2022 | Option exercise | +24,382 | $7.84 | $191.15K | 531,012 |
| Robert J. Gould Director | Jun 6, 2022 | Sale(10b5-1 plan) | −24,382 | $8.10 | $197.49K | 506,630 |
| Robert J. Gould Director | Jun 3, 2022 | Option exercise | +25,551 | $7.84 | $200.32K | 532,181 |
| Robert J. Gould Director | Jun 3, 2022 | Sale(10b5-1 plan) | −25,551 | $7.95 | $203.13K | 506,630 |
| Robert J. Gould Director | Jun 2, 2022 | Option exercise | +16,689 | $7.84 | $130.84K | 523,319 |
| Robert J. Gould Director | Jun 2, 2022 | Sale(10b5-1 plan) | −16,689 | $7.92 | $132.18K | 506,630 |
| Greg Tourangeau Controller | May 6, 2022 | Award | +3,250 | – | – | 16,202 |
| Robert J. Gould Director | Apr 7, 2022 | Option exercise | +5,631 | $7.84 | $44.15K | 512,261 |
| Robert J. Gould Director | Apr 7, 2022 | Sale(10b5-1 plan) | −5,631 | $24.02 | $135.26K | 506,630 |
| Robert J. Gould Director | Apr 5, 2022 | Option exercise | +52,552 | $7.84 | $412.01K | 559,182 |
| Robert J. Gould Director | Apr 5, 2022 | Sale(10b5-1 plan) | −52,552 | $24.26 | $1.27M | 506,630 |
| Robert J. Gould Director | Apr 4, 2022 | Option exercise | +7,235 | $7.84 | $56.72K | 513,865 |
| Robert J. Gould Director | Apr 4, 2022 | Sale(10b5-1 plan) | −7,235 | $24.02 | $173.78K | 506,630 |
| Robert J. Gould Director | Apr 1, 2022 | Sale(10b5-1 plan) | −34,464 | $24.03 | $828.17K | 506,630 |
| Robert J. Gould Director | Apr 1, 2022 | Option exercise | +34,464 | $7.84 | $270.20K | 541,094 |
| Curtis Gale Oltmans SVP, General Counsel | Dec 17, 2021 | Gift | −1,088 | – | – | 1,248 |
| Mark J. Levin Director, 10% owner | Nov 10, 2021 | Other | −1,000,000 | – | – | 3,962,202 |
| Kevin P. Starr 10% owner | Nov 10, 2021 | Other | −1,000,000 | – | – | 3,962,202 |
| Kevin P. Starr 10% owner | Sep 22, 2021 | Other | −1,000,000 | – | – | 4,962,202 |
| Mark J. Levin Director, 10% owner | Sep 22, 2021 | Other | −1,000,000 | – | – | 4,962,202 |
| Bryan Stuart See Remarks, Director | Aug 11, 2021 | Sale(10b5-1 plan) | −28,000 | $23.75 | $665.00K | 0 |
| Bryan Stuart See Remarks, Director | Aug 11, 2021 | Option exercise | +28,000 | $7.84 | $219.52K | 28,000 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Option exercise | +20,714 | $7.84 | $162.40K | 20,714 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Sale(10b5-1 plan) | −20,714 | $17.00 | $352.14K | 0 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Option exercise | +31,071 | $7.84 | $243.60K | 31,071 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Sale(10b5-1 plan) | −31,071 | $18.00 | $559.28K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Tourangeau Greg former officer | Sep 2, 2026 | 14,062 | $54.42K | Sep 2, 2026 | Restricted Stock Awards |
| Ezekowitz Alan Director | Jun 26, 2026 | 18,000 | $64.98K | Jun 26, 2026 | Restricted Stock Units |
| G. Oltmans Curtis Officer | Dec 15, 2025 | 3,452 | $44.88K | Dec 15, 2025 | Employee Stock Purchase Plan |
| Capital Healthcare Fund LP RA 10% Stockholder | Dec 8, 2025 | 4,175,139 | $54.24M | Dec 8, 2025 | Secondary |
| J. Gould Robert Director | Nov 19, 2025 | 45,000 | $437.85K | Nov 19, 2025 | Founders Shares |
| Tourangeau Greg Officer | Mar 8, 2024 | 4,884 | $57.22K | Mar 8, 2024 | Stock option exercises |